Preclinical data demonstrate an increase in PI3K/mTOR activity following PARP inhibition in SCLC models, providing rationale for combination therapy with PARP inhibitors plus PI3K/mTOR inhibitors [82]. The gene discussed is MTOR; the disease is small cell lung carcinoma.